Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride sustained-release tablets, and ursodeoxycholic ACID Capsules. The company also provides bupropion hydrochloride extended-release tablets, and paroxetine and pregabalin extended-release tablets; propafenone hydrochloride extended-release capsules; and sevelamer carbonate tablets. Sinotherapeutics Inc. was founded in 2012 and is headquartered in Shanghai, China.